UK-based e-Therapeutics Plc has appointed Laura Roca-Alonso as chief business officer following an executive restructuring at the company that earlier saw Ali Mortazavi, the former chief executive of Silence Therapeutics Plc, become executive chairman. Dr Roca-Alonso was most recently director of business development at Gyroscope Therapeutics Ltd, a gene therapy company. Before that, she was head of corporate development at Silence.
Dr Roca-Alonso received a PhD from Imperial College London, a master of research degree in biomedicine from University College London and a BSc in biotechnology from Universitat Autònoma de Barcelona, Spain.
e-Therapeutics announced the appointment on 2 April 2020.
Copyright 2020 Evernow Publishing Ltd.